Related Experiment Video
Updated: Aug 2, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 3, 2013
Molecular profiling of prostate cancer
Konrad Huppi1, G V R Chandramouli
1Cancer Prevention Studies Branch, National Cancer Institute/National Institutes of Health, 6116 Executive Blvd., Suite 705, Rockville, MD 20852, USA. huppi@helix.nih.gov
Current Urology Reports
|January 22, 2004
Summary
Identifying new prostate cancer (PCA) biomarkers is crucial for distinguishing aggressive tumors. Gene expression profiling using microarray technology shows promise in pinpointing these markers and improving diagnostic accuracy.
Area of Science:
- Oncology
- Genomics
- Biomarker Discovery
Background:
- Accurate differentiation between aggressive and non-aggressive prostate cancer (PCA) remains a challenge despite advances in detection.
- There is a critical need for novel PCA-specific biomarkers to enhance predictive accuracy.
Purpose of the Study:
- To identify potential biomarkers for distinguishing aggressive PCA using gene expression profiling.
- To evaluate the utility of microarray technology in discovering new diagnostic markers for PCA.
Main Methods:
- Comparative analysis of published microarray studies focusing on prostate cancer gene expression.
- Utilizing multidimensional scaling to analyze global gene expression patterns.
Main Results:
- Several potential biomarkers, including Hepsin, a-methylacyl CoA racemase, and Enhancer of Zeste homologue, have been identified through comparative microarray studies.
- Global gene expression signatures show promise in differentiating between aggressive and non-aggressive PCA, and between PCA and benign prostatic hyperplasia or normal prostate tissue.
Conclusions:
- Microarray technology and gene expression profiling are powerful tools for identifying novel biomarkers in prostate cancer.
- Analysis of global gene expression patterns offers a promising approach for improved clinical classification of prostate cancer.
